Skip to content

Advertisement

BMC Infectious Diseases

What do you think about BMC? Take part in

Open Access
Open Peer Review

This article has Open Peer Review reports available.

How does Open Peer Review work?

Identification of pathogens for differential diagnosis of fever with jaundice in the Central African Republic: a retrospective assessment, 2008–2010

BMC Infectious DiseasesBMC series – open, inclusive and trusted201717:735

https://doi.org/10.1186/s12879-017-2840-8

Received: 25 April 2017

Accepted: 19 November 2017

Published: 29 November 2017

Abstract

Background

Febrile jaundice results clinically in generalized yellow coloration of the teguments and mucous membranes due to excess plasma bilirubin, accompanied by fever. Two types are found: conjugated and unconjugated bilirubin jaundice. Jaundice is a sign in several diseases due to viruses (viral hepatitis and arbovirus), parasites (malaria) and bacteria (leptospirosis). In the Central African Republic (CAR), only yellow fever is included on the list of diseases for surveillance. The aim of this study was to identify the other pathogens that can cause febrile jaundice, for better management of patients.

Methods

Between 2008 and 2010, 198 sera negative for yellow fever IgM were randomly selected from 2177 samples collected during yellow fever surveillance. Laboratory analyses targeted four groups of pathogens: hepatitis B, C, delta and E viruses; dengue, chikungunya, Zika, Crimean–Congo haemorrhagic fever, West Nile and Rift Valley arboviruses; malaria parasites; and bacteria (leptospirosis).

Results

Overall, 30.9% sera were positive for hepatitis B, 20.2% for hepatitis E, 12.3% for hepatitis C and 8.2% for malaria. The majority of positive sera (40.4%) were from people aged 16–30 years. Co-infection with at least two of these pathogens was also found.

Conclusion

These findings suggest that a systematic investigation should be undertaken of infectious agents that cause febrile jaundice in the CAR.

Keywords

Febrile jaundiceDifferential diagnosisCentral African Republic

Background

Febrile jaundice, a frequent symptom of certain infectious diseases, appears clinically as a generalized yellow coloration of the integuments and mucous membranes, due to excess plasma bilirubin, and is accompanied by fever >37.5 °C in the morning and 38 °C in the evening. It may be due secondarily to the release of a pyrogenic substance or of haemoglobin into the blood due to haemolysis or to cholestasis, with a decrease or halt in biliary secretion of intra- or extra-hepatic origin [14]. In low- and middle-income countries, predominantly in sub-Saharan Africa, febrile jaundice usually occurs in the presence of parasitic infections (malaria, toxoplasmosis, schistosomiasis), bacterial infections (typhoid, typhus, borreliosis, leptospirosis) or viral infections (hepatitis and Lassa, Marburg, Ebola, Crimean–Congo and Hantaan viral haemorrhagic fevers, cytomegalovirus, mumps, measles, rubella and Coxackievirus) and is sometimes present in sickle-cell disease [311]. These infections are major public health problems in the region, and understanding of their local epidemiology could indicate differential diagnoses [12].

For over a decade, the World Health Organization (WHO) has conducted epidemiological surveillance for yellow fever in countries such as the Central African Republic (CAR). Operationally, any case of febrile jaundice is considered a suspected case of yellow fever and must be tested for yellow fever antigen (immunoglobulin M, IgM) in a qualified national laboratory. Samples that are negative for IgM suggest the involvement of other pathogens. In the CAR, 3220 suspected cases of yellow fever were reported to the reference laboratory for haemorrhagic fever at the Institut Pasteur of Bangui between 2007 and 2012; of these, 55 were positive [13]. We designed an exploratory study to identify the pathogens in the samples that were negative for yellow fever.

Methods

Database and target population

Data from nationwide serosurveillance for yellow fever between 1 January 2008 and 31 December 2010 were analysed retrospectively. The data are in the Epi Info database (Centers for Diseases Control and Prevention, Atlanta (GA), United States of America), which also contains information on the samples and sociodemographic data on the donors. The patients who gave samples met the WHO standard definition of suspected cases of yellow fever, i.e. any person with acute onset of fever and jaundice appearing within 14 days of onset of the first symptoms [14]. The samples consisted of 1–5 mL of venous blood drawn into dry tubes and transported in refrigerated sample carriers at 4–8 °C to the national reference laboratory at the Institut Pasteur of Bangui. The transport was ensured by trained focal points at CAR regional health facilities. The data obtained for each patient were: age, sex, location, symptoms (fever and jaundice or any sign of bleeding), history of vaccination against yellow fever, date of onset of symptoms and dates of blood sampling and transport to the laboratory. Serum was separated from each patient’s blood sample within 24 h and tested for yellow fever virus-specific fever IgM by enzyme-linked immunosorbent assay (ELISA). Positive results with ELISA were confirmed by quantitative polymerase chain reaction (qPCR). The remaining serum samples were stored at −20 °C at the Institut Pasteur of Bangui.

Selection of samples and identification of pathogens

As the purpose of this study was to differentiate yellow fever from other infections that present with similar features (acute fever and jaundice), only samples that were negative for yellow fever were selected. The codes of 2177 samples negative for yellow fever IgM were entered on an Excel spreadsheet from laboratory registers, and 198 samples were randomly selected for this study on the basis of the availability of testing reagents. The corresponding serum samples were identified in the storage freezer. Four groups of pathogens were targeted: hepatitis B, C, delta and E viruses; dengue, chikungunya, Zika, Crimean–Congo haemorrhagic fever, West Nile and Rift Valley arboviruses; malaria parasites; and bacteria (leptospirosis). The appropriate laboratory technique was used to identify each pathogen.

ELISA was used to screen for hepatitis, with a Murex™ Diasorin kit for hepatitis B virus (to detect hepatitis B surface antigen), antigen detection of hepatitis delta (HD) virus and a Monolisa™ HCV Ag-Ab ULTRA kit (Bio-Rad) for hepatitis C virus (HCV). Leptospira infection was diagnosed with the Panbio Leptospira IgM ELISA (Standard Diagnostics, Republic of Korea). The results were interpreted according to the manufacturers’ recommendations. Hepatitis E (HEV), dengue (DENV), chikungunya (CHIKV), Zika virus (ZIKV), Crimean–Congo haemorrhagic fever (CCHFV), West Nile virus (WNV) and Rift Valley (RVFV) infections were detected by qPCR [1522]. The sequences of primers and probes used to identify these viruses are presented in Table 1.
Table 1

Primers and probes used to detect arbovirus and hepatitis E virus

Primers and probes

Nucleic acid sequences of primers and probes

qPCR Zika virus (ZIKV)

 ZIKV forward

5-nt9271AARTACACATACCARAACAAAgTggT9297–3’

 ZIKV reverse

5′ nt9352-TCCRCTCCCYCTYTggTCTTg-9373 -3’

 ZIKV probe

nt 9304-FAM-CTYAgACCAgCTgAAR-BBQ-9320

qPCR Dengue total (DENV 1–4 system)

 DENT forward

5′- AGGACYAGAGGTTAGAGGAGA - 3’

 DENT reverse

5′- CGYTCTGTGCCTGGAWTGAT −3’

 DENT probe

FAM-ACAGCATATTGACGCTGGGARAGACC-TAMRA

qPCR Dengue subtypes (DENV1, DENV2, DENV3)

 DEN1 forward

5′ ATACCYCCAACAGCAGGAATT - 3’

 DEN1 reverse

5′ AGCATRAGGAGCATGGTCAC −3’

 DEN1 probe

FAM-TTGGCTAGATGGRGCTCATTCAAGAAGAAT-TAMRA

 DEN2 forward

5′ TGGACCGACAAAGACAGATTCTT 3’

 DEN2 reverse

5′ CGYCCYTGCAGCATTCCAA 3’

 DEN2 probe

FAM-CGCGAGAGAAACCGCGTGTCRACTGT-TAMRA

 DEN3 forward

5′ AAGACGGGAAAACCGTCTATCAA 3’

 DEN3 reverse

5′ TTGAGAATCTCTTCGCCAACTG 3’

 DEN3 probe

FAM-ATGCTGAAACGCGTGAGAAACCGTGT-TAMRA

qPCR Chikungunya (CHIK)

 CHIK forward

5′- AAGCTYCGCGTCCTTTACCAAG - 3’

 CHIK reverse

5′- CCAAATTGTCCYGGTCTTCCT −3’

 CHIK probe

FAM-CCAATGTCYTCMGCCTGGACACCTTT-TAMRA

qPCR Rift Valley fever virus (RVFV)

 RVFV forward

5′- AAA ggA ACA ATg gAC TCT ggT CA - 3’

 RVFV reverse

5′- CAC TTC TTA CTA CCA TTC CTC CAA T − 3’

 RVFV probe

FAM-AAA gCT TTg ATA TCT CTC AgT gCC CCA A -TAMRA

qPCR West Nile virus (WNV)

 WNV3p forward

5′ Agg TTA gWg gAg ACC CCg T - 3’

 WNV3p reverse

5′ ggT TgT gCA gAg CAg AAg ATC −3’

 WNV3p probe

FAM-CGGTTCCGGCGGTGGTTTCT-TAMRA

Conventional PCR Crimean-Congo haemorrhagic fever virus (CCHFV)

 CCHFV forward

5′ – TGGACACCTTCACAAACTC - 3’

 CCHFV reverse

5′ – GACAAATTCCCTGCACCA - 3’

qPCR Hepatitis E virus (HEV)

 HEV forward

5′ GCCCGGTCAGCCGTCTGG −3’

 HEV reverse

5′-CTGAGAATCAACCCGGTCAC −3’

 HEV probe

FAM-CGGTTCCGGCGGTGGTTTCT-TAMRA

Malaria was diagnosed with Standard Diagnostics Bioline Ag-Pf and Ag-pan (Standard Diagnostics, Ref 05FK60, Republic of Korea), which contains antibodies targeting both PfHRP2 and lactate dehydrogenase specific to P. falciparum and other Plasmodium species (P. vivax, P. ovale and P. malariae).

Data analysis

Stata 11.0 software was used to calculate proportions of test results. The results were compared according to sociodemographic characteristics with the chi-2 test. Statistical significance was assessed at P < 0.05.

Results

Evidence of infection with at least one pathogen was found in 49.0% of samples (n = 97). Males under 35 years of age were the most commonly infected, but the difference was not statistically significant (P = 0.567 and 0.118, respectively). Of the 131 samples, 66.2% were from Bangui, the capital of the CAR, and its surrounding area, Ombella M’Poko (Table 2).
Table 2

Distribution of positive results for pathogens in differential diagnosis of yellow fever according to sociodemographic characteristics in the CAR (2008–2010)

Characteristic

Any positive result

Negative result

P

No.

%

No.

%

Age (years)

< 15

35

52.2

32

47.8

0.567

 

16–24

24

52.2

22

47.8

 
 

25–34

21

50.0

21

50.0

 
 

≥ 35

17

39.5

26

60.5

 

Sex

Male

43

43.4

56

56.6

0.118

 

Female

54

54.5

45

45.5

 

Province of residence

Bangui

41

51.9

38

48.1

0.446

 

Bambari

1

50.0

1

50.0

 
 

Basse Kotto

6

40.0

9

60.0

 
 

Haute Kotto

3

60.0

2

40.0

 
 

Kembe

2

33.3

4

66.7

 
 

Lobaye

0

0.0

7

100.0

 
 

Mbomou

3

75.0

1

25.0

 
 

Nana Mambere

1

25.0

3

75.0

 
 

Ombela-M’poko

27

51.9

25

48.1

 
 

Ouaka

1

100.0

0

0.0

 
 

Ouham

5

55.7

4

44.3

 
 

Ouham Pende

5

50.0

5

50.0

 
 

Sangha Mbaere

0

0.0

1

100.0

 
 

Vakaga

2

66.7

1

33.3

 
The predominant pathogens were hepatitis B (51.5%; 50/97), E (33.0%; 32/97) and C viruses (20.6%; 20/97). Co-infections were frequent, at a rate of 25.8% (25/97). Analyses for other pathogens (leptospira, DENV, CHIK and Zika, CCHV, WNV and RVFV) yielded negative results. The results for 16 patients showed co-infection with hepatitis B, E and C viruses (Table 3).
Table 3

Pathogens identified in samples negative for yellow fever IgM, CAR, 2008–2010

Infectious agent

No. of samples testeda

No. positive (%)

HBsAg

162

32 (19.8)

HEVb

198

27 (13.6)

HCVAg

162

9 (5.6)

P. falciparum

198

4 (2.0)

Anti-HDc

50

17 (34.0)

HEV + HBsAg

162

6 (3.7)

HBsAg + HCVAg

162

4 (2.5)

HBsAg + P. falciparum

162

4 (2.5)

P. falciparum + HCVAg

162

3 (1.9)

HCVAg + HEV

162

2 (1.2)

HEV + P. falciparum

198

2 (1.0)

HBsAg + HEV + P. falciparum

162

2 (1.2)

HBsAg + HEV + HCVAg

162

1 (0.6)

HBSAg + P. falciparum + HCVAg

162

1 (0.6)

Other pathogensd

198

0 (0,0)

aAfter testing sera for leptospirosis; dengue arbovirus; chikungunya, Zika, Crimean–Congo haemorrhagic fever, West Nile and Rift Valley viruses; and P. falciparum, sufficient quantities of serum remained for testing only a further 162 samples

bHepatitis E virus, tested with qPCR

cHepatitis delta virus

dLeptospirosis; DENV; CHIK, ZIKV, CCHFV, WNV and RVFV

Discussion

Almost half the samples from patients presenting with fever and jaundice contained at least one infectious agent. Hepatitis B, C and E viruses were the most common pathogens identified in our samples; these infections are endemic in the CAR [23, 24]. The prevalence of hepatitis B virus infection was higher than that found previously in the CAR by Komas et al., at 10.6% [25]; however, those authors collected samples from apparently healthy individuals, while we studied patients presenting with clinical symptoms.

HDV is a satellite of hepatitis B virus, and infection with this virus aggravates acute and chronic liver disease. A review of the literature shows strong variations in the prevalence of this virus among Africans seropositive for HbsAg, and the presence of this marker may constitute support for the argument that it plays a role in the development of HBsAg-associated liver diseases [26]. A study conducted in the CAR in 1989 showed that delta virus was the cause of fulminating hepatitis with severe jaundice in 124 cases [27]. In another study, however, it was much more common in patients with chronic liver disease [28].

Hepatitis E virus is endemic in central Africa, due mainly to poor environmental hygiene, a deteriorating health network and very poor epidemiological surveillance. Hepatitis E virus outbreaks were reported, for example, in 2002, 2004 and 2005 in Bangui [29, 30], and imported hepatitis E virus was documented in 2011, prompting implementation of the International Health Regulations (2005) in the CAR [31].

Severe malaria caused exclusively by P. falciparum in the CAR is also considered in people presenting with febrile jaundice, as this disease is endemic in the area. In severe malaria, jaundice is related to severe haemolysis, hepatocellular damage, drug toxicity or a combination [3234]. Co-infections with these pathogens are alarming because of their potential synergy in hepatitis dysfunction. The co-existence of malaria and viral hepatitis in developing countries like the CAR may thus present a diagnostic dilemma and severe complications and delay treatment [35].

We did not identify most of the less prevalent infections, such as leptospirosis, dengue, chikungunya, Zika, Crimean–Congo haemorrhagic fever, West Nile or Rift Valley fever, despite the fact that Africa has become a hotspot for leptospirosis research by microbiologists working to differentiate the causal agents of yellow fever [36].

More than half (51.0%) the cases of febrile jaundice had none of the studied pathogens. This was to be expected, as other differential diagnoses of fever with jaundice include community-acquired sepsis, amoebic fever, acute cholecystitis and choledocholithiasis [37].

The main limitation of this study is the relatively small number of samples selected for testing, which may therefore not adequately represent the target population. Specifically, the proportion of people with HCV infection in this sample would not be representative of the overall proportion in the CAR, as febrile jaundice is present in only a subset of people with newly acquired infection. Another limitation is that only samples that were negative for yellow fever were tested. Some of the samples positive for yellow fever virus might also yield positive results for other infectious pathogens [38] that have life-threatening synergistic effects.

Conclusions

This study shows that acute hepatitis virus infections are still an important problem in the CAR. It is therefore essential to scale up hepatitis B vaccination and improve sanitation and environmental hygiene. Moreover, clinicians should be sensitized to the diagnostic dilemma of patients presenting with febrile jaundice. This study provides data on the prevalence of these diseases and the possibility of epidemics. Nationwide surveillance for yellow fever should be complemented by a survey of hepatitis viruses and other emerging haemorrhagic infections.

Abbreviations

CAR: 

Central African Republic

CCHFV: 

Crimean-Congo haemorrhagic fever virus

CHIK: 

Chikungunya

DEN: 

Dengue

DENT: 

Dengue total

DENV: 

Dengue virus

ELISA: 

Enzyme-linked immunosorbent assay

HBsAg: 

Hepatitis B surface antigen

HCV: 

Hepatitis C virus

HDV: 

Hepatitis delta virus

HEV: 

Hepatitis E virus

IgM: 

Immunoglobulin M

qPCR: 

Quantitative polymerase chain reaction

RVFV: 

Rift Valley fever virus

WHO: 

World Health Organization

WNV: 

West Nile virus

ZIKV: 

Zika virus

Declarations

Acknowledgements

We thank the Ministry of Health, health professionals in the various health facilities, the WHO Representative and nongovernmental organizations in the CAR for transporting samples to the laboratory and for diagnostic reagents. We also thank all the patients who participated in this study. We are also grateful to Professeur Elisabeth Heseltine for her support in editing this manuscript.

Funding

The Institut Pasteur de Bangui and the Ministry of Health in the CAR supported the study financially. National surveillance of yellow fever and the pathogens targeted in this analysis was funded by WHO.

Availability of data and materials

The datasets generated and analysed during the current study is not publicly available because it contains potentially identifiable information but is available from the corresponding author on reasonable request.

Authors’ contributions

CLBG supervised the field activities, participated in collecting data, analysed and interpreted the data and wrote the manuscript. AM prepared the questionnaire and analysed and interpreted the data. GT contributed to writing the manuscript. XK performed the ELISA tests. UV contributed to the analysis and interpretation of the data. EN designed the study and directed it, supervised all the field activities and contributed to the analysis and interpretation of the data. All the authors participated in writing this draft and approved the final version of the manuscript for publication.

Ethics approval and consent to participate

This surveillance programme was approved by the expert committee for the yellow fever control programme of the Ministry of Health in CAR. As national surveillance is performed for transmissible diseases subject to mandatory declaration in the country (yellow fever and other haemorrhagic fevers), patient consent was not necessary.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Authors’ Affiliations

(1)
Institut Pasteur of Bangui, Virology Department
(2)
Institut Pasteur of Bangui, Epidemiology Service
(3)
Hôpital de l’Amitié, Ministry of Public Health, Population and AIDS Control

References

  1. Chung JP, Kim KW, Chi HS, Lee SI, Shin ET, Cho JH, et al. Obstructive jaundice due to compression of the common hepatic duct by right hepatic artery--a case associated with the absence of the lateral segment of the left hepatic lobe. Yonsei Med J. 1994;35(2):231–8.View ArticlePubMedGoogle Scholar
  2. Chang K, Yan JJ, Lee HC, Liu KH, Lee NY, Ko WC, Acute h. With or without jaundice: a predominant presentation of acute Q fever in southern Taiwan. J Microbiol Immunol Infect. 2004;37(2):103–8.PubMedGoogle Scholar
  3. Shah S, Ali L, Sattar RA, Aziz T, Ansari T, Ara J. Malarial hepatopathy in falciparum malaria. J Coll Physicians Surg Pak. 2009;19(6):367–70.PubMedGoogle Scholar
  4. L'Azou M, Succo T, Kamagate M, Ouattara A, Gilbernair E, Adjogoua E, et al. Dengue: etiology of acute febrile illness in Abidjan, cote d'Ivoire, in 2011–2012. Trans R Soc Trop Med Hyg. 2015;109(11):717–22.View ArticlePubMedPubMed CentralGoogle Scholar
  5. Schindler M, Kreplak N, Acevedo L, Damis H, Marquez G, Ardaiz MC. Febrile cholestatic jaundice as an initial manifestation of Hodgkin's disease. Medicina (Buenos Aires). 2014;74(1):60–1.Google Scholar
  6. Yesilyurt M, Kilic S, Gursoy B, Celebi B, Yerer M. Two cases of acute hepatitis associated with Q fever. Mikrobiyol Bul. 2012;46(3):480–7.PubMedGoogle Scholar
  7. Taddio A, Pellegrin MC, Centenari C, Filippeschi IP, Ventura A, Maggiore G. Acute febrile cholestatic jaundice in children: keep in mind Kawasaki disease. J Pediatr Gastroenterol Nutr. 2012;55(4):380–3.View ArticlePubMedGoogle Scholar
  8. Juwah AI, Nlemadim A, Kaine W. Clinical presentation of severe anemia in pediatric patients with sickle cell anemia seen in Enugu, Nigeria. Am J Hematol. 2003;72(3):185–91.View ArticlePubMedGoogle Scholar
  9. Wolfsen HC, Bolen JW, Bowen JL, Fenster LF. Fulminant herpes hepatitis mimicking hepatic abscesses. J Clin Gastroenterol. 1993;16(1):61–4.View ArticlePubMedGoogle Scholar
  10. Rose HD, Lentino JR, Mavrelis PG, Rytel MW. Jaundice associated with nonhepatic Staphylococcus aureus infection. Does teichoic acid have a role in pathogenesis? Dig Dis Sci. 1982;27(11):1046–50.View ArticlePubMedGoogle Scholar
  11. World Health Organization: District guidelines for yellow fever surveillance (WHO/EPI/GEN/98.09) (http://www.who.int/csr/resources/publications/yellowfev/whoepigen9809.pdf, accessed 12 June 2015).
  12. Isa SE, Onyedibe KI, Okolo MO, Abiba AE, Mafuka JS, Simji GS, et al. A 21-year-old student with fever and profound jaundice. PLoS Negl Trop Dis. 2014;8(1):e2534.View ArticlePubMedPubMed CentralGoogle Scholar
  13. Rachas A, Nakoune E, Bouscaillou J, Paireau J, Selekon B, Senekian D, et al. Timeliness of yellow fever surveillance, Central African Republic. Emerg Infect Dis. 2014;20(6):1004–8.View ArticlePubMedPubMed CentralGoogle Scholar
  14. World Health Organization. Yellow fever surveillance and outbreak response: revision of case definitions, October 2010. Wkly Epidemiol Rec. 2010;85:461–72.Google Scholar
  15. Nabeth P, Cheikh DO, Lo B, Faye O, Vall IO, Niang M, et al. Crimean-Congo hemorrhagic fever, Mauritania. Emerg Infect Dis. 2004;10(12):2143–9.View ArticlePubMedPubMed CentralGoogle Scholar
  16. Saluzzo JF, Anderson GW Jr, Hodgson LA, Digoutte JP, Smith JF. Antigenic and biological properties of Rift Valley fever virus isolated during the 1987 Mauritanian epidemic. Res Virol. 1989;140(2):155–64.View ArticlePubMedGoogle Scholar
  17. SJ W, Pal S, Ekanayake S, Greenwald D, Lara S, Raviprakash K, et al. A dry-format field-deployable quantitative reverse transcriptase-polymerase chain reaction assay for diagnosis of dengue infections. Am J Trop Med Hyg. 2008;79(4):505–10.Google Scholar
  18. Vasickova P, Kralik P, Slana I, Pavlik I. Optimisation of a triplex real time RT-PCR for detection of hepatitis E virus RNA and validation on biological samples. J Virol Meth. 2012;180(1–2):38–42.View ArticleGoogle Scholar
  19. Faye O, Diallo D, Diallo M, Weidmann M, Sall AA. Quantitative real-time PCR detection of Zika virus and evaluation with field-caught mosquitoes. Virol J. 2013;10:311.View ArticlePubMedPubMed CentralGoogle Scholar
  20. Yap G, Pok KY, Lai YL, Hapuarachchi HC, Chow A, Leo YS, et al. Evaluation of chikungunya diagnostic assays: differences in sensitivity of serology assays in two independent outbreaks. PLoS Negl Trop Dis. 2010;4(7):e753.View ArticlePubMedPubMed CentralGoogle Scholar
  21. Lanciotti RS, Kerst AJ, Nasci RS, Godsey MS, Mitchell CJ, Savage HM, et al. Rapid detection of West Nile virus from human clinical specimens, field-collected mosquitoes, and avian samples by a TaqMan reverse transcriptase-PCR assay. J Clin Microbiol. 2000;38(11):4066–71.PubMedPubMed CentralGoogle Scholar
  22. Drosten C, Gottig S, Schilling S, Asper M, Panning M, Schmitz H, et al. Rapid detection and quantification of RNA of Ebola and Marburg viruses, Lassa virus, Crimean-Congo hemorrhagic fever virus, Rift Valley fever virus, dengue virus, and yellow fever virus by real-time reverse transcription-PCR. J Clin Microbiol. 2002;40(7):2323–30.View ArticlePubMedPubMed CentralGoogle Scholar
  23. Pawlotsky JM, Belec L, Gresenguet G, Deforges L, Bouvier M, Duval J, et al. High prevalence of hepatitis B, C, and E markers in young sexually active adults from the Central African Republic. J Med Virol. 1995;46(3):269–72.View ArticlePubMedGoogle Scholar
  24. Bekondi C, Olinger CM, Boua N, Talarmin A, Venard V, Muller CP, et al. Characterization of hepatitis B virus strains from the Central African Republic: preliminary results. Pathol Biol (Paris). 2008;56(5):310–3.View ArticleGoogle Scholar
  25. Komas NP, Vickos U, Hubschen JM, Bere A, Manirakiza A, Muller CP, et al. Cross-sectional study of hepatitis B virus infection in rural communities, Central African Republic. BMC Infect Dis. 2013;13:286.View ArticlePubMedPubMed CentralGoogle Scholar
  26. Roingeard P, Sankale JL, Dubois F, Diouf A, Bacha A, Mboup S, et al. Infection due to hepatitis delta virus in Africa: report from Senegal and review. Clin Infect Dis. 1992;14(2):510–4.View ArticlePubMedGoogle Scholar
  27. Lesbordes JL, Ravisse P, Georges AJ, Beuzit Y, Ave P, Enamra D, et al. Role of delta viruses in fulminating hepatitis in Central Africa. Ann Med Interne (Paris). 1987;138(3):199–201.Google Scholar
  28. Andernach IE, Leiss LV, Tarnagda ZS, Tahita MC, Otegbayo JA, Forbi JC, et al. Characterization of hepatitis delta virus in sub-Saharan Africa. J Clin Microbiol. 2014;52(5):1629–36.View ArticlePubMedPubMed CentralGoogle Scholar
  29. Goumba AI, Konamna X, Komas NP. Clinical and epidemiological aspects of a hepatitis E outbreak in Bangui, Central African Republic. BMC Infect Dis. 2011;11:93.View ArticlePubMedPubMed CentralGoogle Scholar
  30. Escriba JM, Nakoune E, Recio C, Massamba PM, Matsika-Claquin MD, Goumba C, et al. Hepatitis E, Central African Republic. Emerg Infect Dis. 2008;14(4):681–3.View ArticlePubMedPubMed CentralGoogle Scholar
  31. World Health Organization: International Health Regulations (2005). Geneva; 2005.Google Scholar
  32. Abro AH, Ustadi AM, Abro HA, Abdou AS, Younis NJ, Akaila SI. Jaundice with hepatic dysfunction in P. falciparum malaria. J Coll Physicians Surg Pak. 2009;19(6):363–6.PubMedGoogle Scholar
  33. Mazumder R, Mishra RK, Mazumder H, Mukherjee P. Jaundice in falciparum malaria--some prospective observations. J Indian Med Assoc. 2002;100(5):312–4.PubMedGoogle Scholar
  34. Mishra D, Chaturvedi D, Mantan M. Typhoid fever and viral hepatitis. Indian J Pediatr. 2008;75:509–10.View ArticlePubMedGoogle Scholar
  35. Zaki S, Asif S, Dadge D, Shanbag P. Co-existence of viral hepatitis with malaria. J Postgrad Med. 2009;55(3):233.View ArticlePubMedGoogle Scholar
  36. Porterfield JS. Yellow fever in West Africa: a retrospective glance. BMJ. 1989;299(6715):1555–7.View ArticlePubMedPubMed CentralGoogle Scholar
  37. Gordon MA, Walsh AL, Chaponda M, Soko D, Mbvwinji M, Molyneux ME, et al. Bacteraemia and mortality among adult medical admissions in Malawi – predominance of non-typhi salmonellae and Streptococcus pneumoniae. J Inf Secur. 2001;42(1):44–9.Google Scholar
  38. Baba M, Logue CH, Oderinde B, Abdulmaleek H, Williams J, Lewis J, et al. Evidence of arbovirus co-infection in suspected febrile malaria and typhoid patients in Nigeria. J Infect Dev Countries. 2013;7(1):51–9.Google Scholar

Copyright

© The Author(s). 2017

Advertisement